BMICY News 9.6000 Bionomics Ltd Sp ADR (BMICY)
Post# of 273317
Posted On: 04/16/2014 2:49:06 PM
Bionomics Ltd Sp ADR (BMICY) 9.6000 $BMICY
Bionomics Features at American Association for Cancer Research Annual Meeting
GlobeNewswire - Mon Apr 07, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) is delivering three poster presentations at the 105th Annual American Association for Cancer Research (AACR) meeting at the San Diego Convention Center this week.
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer
GlobeNewswire - Mon Feb 03, 6:30AM CST
-- 10 out of 15 patients with positive response in Phase I
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Breast Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Breast Cancer
M2 - Tue Nov 05, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfkggb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Breast Cancer. - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Kyowa Hakko Kirin Co., Ltd. - Celsion Corporation - Biogen Idec Inc. - Amgen Inc. - A&G Pharmaceutical, Inc. - Novartis AG - Aphios Corporation - Biocon Limited - Chong Kun Dang Pharmaceutical - Marshall Edwards, Inc. - Basilea Pharmaceutica Ltd. - Bionomics Limited - MultiCell Technologies, Inc. - Neuren Pharmaceuticals Limited - Natco Pharma Limited - Sareum Holdings plc - TRACON Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - DEKK-TEC, Inc. - Regulon Inc. - AUS Bio Limited - EirGen Pharma Ltd. - Epeius Biotechnologies Corporation - Ampio Pharmaceuticals, Inc. - CytomX, LLC. For more information visit http://www.researchandmarkets.com/research/hf...ast_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Pain - Pipeline Review, H2 2013
M2 - Tue Nov 05, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2dmrd/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Scope - A snapshot of the global therapeutic scenario for Chronic Pain. - A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Chronic Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Examples of Companies Mentioned - Afferent Pharmaceuticals - Alkermes - AlphaRx - Benitec - BioAlliance Pharma - Bionomics Limited - CombinatoRxrporated - Daewoong Pharmaceutical - Daiichi Sankyo - Debiopharm - Diamyd Medical - Eli Lilly and Company - Elite Pharmaceuticals - Esteve - Grunenthal - Immupharma - Kineta - Labtec - Nektar Therapeutics - Neorphys - Pain Therapeutics - Pfizer - Phosphagenics - QRxPharma - RaQualia Pharma - Sanofi-Aventis - Trevena For more information visit http://www.researchandmarkets.com/research/b2...ronic_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics to Present Cancer Compounds at AACR International Conference
GlobeNewswire - Fri Oct 18, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) will present posters on both BNC101 and BNC105 at the American Association for Cancer Research (AACR) International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
Research and Markets: Gynecological Cancer - Pipeline Review, H1 2013 Features Players Such as Amgen Inc., Bionomics Limited and Novogen Limited
Business Wire - Wed Jun 05, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmb3bd/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
Manufacture of BNC101 Commences at Lonza
GlobeNewswire - Tue Apr 23, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studies.
Bionomics Features at American Association for Cancer Research Annual Meeting
GlobeNewswire - Mon Apr 07, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) is delivering three poster presentations at the 105th Annual American Association for Cancer Research (AACR) meeting at the San Diego Convention Center this week.
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer
GlobeNewswire - Mon Feb 03, 6:30AM CST
-- 10 out of 15 patients with positive response in Phase I
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Breast Cancer - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Breast Cancer
M2 - Tue Nov 05, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfkggb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Breast Cancer. - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Kyowa Hakko Kirin Co., Ltd. - Celsion Corporation - Biogen Idec Inc. - Amgen Inc. - A&G Pharmaceutical, Inc. - Novartis AG - Aphios Corporation - Biocon Limited - Chong Kun Dang Pharmaceutical - Marshall Edwards, Inc. - Basilea Pharmaceutica Ltd. - Bionomics Limited - MultiCell Technologies, Inc. - Neuren Pharmaceuticals Limited - Natco Pharma Limited - Sareum Holdings plc - TRACON Pharmaceuticals, Inc. - Nexgenix Pharmaceuticals, LLC - DEKK-TEC, Inc. - Regulon Inc. - AUS Bio Limited - EirGen Pharma Ltd. - Epeius Biotechnologies Corporation - Ampio Pharmaceuticals, Inc. - CytomX, LLC. For more information visit http://www.researchandmarkets.com/research/hf...ast_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Chronic Pain - Pipeline Review, H2 2013
M2 - Tue Nov 05, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2dmrd/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Scope - A snapshot of the global therapeutic scenario for Chronic Pain. - A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Chronic Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Examples of Companies Mentioned - Afferent Pharmaceuticals - Alkermes - AlphaRx - Benitec - BioAlliance Pharma - Bionomics Limited - CombinatoRxrporated - Daewoong Pharmaceutical - Daiichi Sankyo - Debiopharm - Diamyd Medical - Eli Lilly and Company - Elite Pharmaceuticals - Esteve - Grunenthal - Immupharma - Kineta - Labtec - Nektar Therapeutics - Neorphys - Pain Therapeutics - Pfizer - Phosphagenics - QRxPharma - RaQualia Pharma - Sanofi-Aventis - Trevena For more information visit http://www.researchandmarkets.com/research/b2...ronic_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics to Present Cancer Compounds at AACR International Conference
GlobeNewswire - Fri Oct 18, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) will present posters on both BNC101 and BNC105 at the American Association for Cancer Research (AACR) International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
Research and Markets: Gynecological Cancer - Pipeline Review, H1 2013 Features Players Such as Amgen Inc., Bionomics Limited and Novogen Limited
Business Wire - Wed Jun 05, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmb3bd/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
Manufacture of BNC101 Commences at Lonza
GlobeNewswire - Tue Apr 23, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studies.
(0)
(0)